Summary: Newsweek highlights the completion of the Capstone Challenge fundraising campaign, the progress of MAPS-sponsored clinical trials of MDMA-assisted psychotherapy for PTSD, and the Food and Drug Administration (FDA) granting breakthrough therapy designation to MDMA for the treatment of PTSD. “The group, Multidisciplinary Association for Psychedelic Studies (MAPS), announced $30 million in donations, which it will use to test the efficacy of a psychedelic-drug therapy that uses MDMA and talk therapy to treat patients with post-traumatic stress disorder (PTSD).”
Originally appearing here.
